Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)

por Papp, K., Menter, A., Leonardi, C., Soung, J., Weiss, S., Pillai, R., Jacobson, A.
Publicado 2020

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from t...

por Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.
Publicado 2018

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlle...

por Reich, K., Gooderham, M., Green, L., Bewley, A., Zhang, Z., Khanskaya, I., Day, R.M., Goncalves, J., Shah, K., Piguet, V., Soung, J.
Publicado 2016